Breaking News, Collaborations & Alliances

Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B

Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.

By: Contract Pharma

Contract Pharma Staff

Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, has entered a collaboration and license agreement with Roche to apply Dyno’s CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) diseases and liver-directed therapies for the portfolio of both Roche and Spark Therapeutics, a member of the Roche Group.   Dyno’s proprietary CapsidMap platform represents a transfor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters